International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.12814199
Original Research Article
To Compare the Efficacy of Application of 5% EMLA Cream with Betamethasone Gel 0.05% for Postoperative Sore Throat (Post) Following General Anaesthesia
Published
Oct. 29, 2024
Abstract

Background: Postoperative sore throat (POST) is a common complication following general anesthesia with endotracheal intubation. This study compared the efficacy of 5% EMLA cream and betamethasone gel 0.05% applied on the endotracheal tube cuff in preventing POST.Methods: In this prospective, randomized study, 50 adult patients undergoing general anesthesia were allocated to receive either 5% EMLA cream (n=25) or betamethasone gel 0.05% (n=25) on the endotracheal tube cuff. The incidence and severity of POST, cough, and hoarseness of voice were assessed at 0, 6, and 24 hours post-extubation. Hemodynamic parameters and adverse events were also recorded.Results: The incidence of POST at 6 hours was significantly lower in the EMLA group (8%) compared to the betamethasone group (32%) (p=0.034). The severity of POST at 6 hours was also significantly lower in the EMLA group (0.1 ± 0.4) compared to the betamethasone group (0.4 ± 0.7) (p=0.048). The incidences of postoperative cough and hoarseness of voice were lower in the EMLA group at all time points, but the differences were not statistically significant (p>0.05). Hemodynamic parameters and adverse event profiles were comparable between the groups.Conclusion: The application of 5% EMLA cream on the endotracheal tube cuff significantly reduced the incidence and severity of POST at 6 hours compared to betamethasone gel 0.05% in adult patients undergoing general anesthesia. EMLA cream is an effective and safe alternative for preventing POST in this patient population.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
72 Views
487 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved